Robin K Kelley

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls
    Robin K Kelley
    Helen Diller Family Comprehensive Cancer Center and The Liver Center, University of California San Francisco UCSF, 550 16th St, Box 3211, San Francisco, CA, 94143, USA
    BMC Cancer 15:206. 2015
  2. pmc Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates
    R K Kelley
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco UCSF, San Francisco, CA 94143, USA
    Ann Oncol 24:1900-7. 2013
  3. ncbi request reprint Predictive biomarkers in advance of a companion drug: ahead of their time?
    Robin K Kelley
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA
    J Natl Compr Canc Netw 10:303-9. 2012
  4. pmc Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
    Robin K Kelley
    University of California, San Francisco, The Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 10:73-80. 2011
  5. pmc Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer
    Robin K Kelley
    Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
    J Natl Compr Canc Netw 9:13-25. 2011
  6. ncbi request reprint Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    Am J Clin Oncol 35:411-7. 2012
  7. doi request reprint A review of hepatocellular carcinoma (HCC) staging systems
    Somasundaram Subramaniam
    Stanford Cancer Institute, Stanford, California, USA
    Chin Clin Oncol 2:33. 2013
  8. ncbi request reprint A Case Series of Patients with HER2-Overexpressed Primary Metastatic Gastroesophageal Adenocarcinoma
    Pelin Cinar
    Division of Hematology Oncology, Department of Medicine, University of California, San Francisco, CA, U S A
    Anticancer Res 34:7357-60. 2014
  9. doi request reprint Multidisciplinary management of hepatocellular carcinoma
    Jennifer Guy
    Department of Medicine, University of California San Francisco, San Francisco, California, USA
    Clin Gastroenterol Hepatol 10:354-62. 2012
  10. doi request reprint Novel therapeutics in hepatocellular carcinoma
    Robin K Kelley
    From the University of California, San Francisco, San Francisco, CA
    Am Soc Clin Oncol Educ Book 2013:137-42. 2013

Collaborators

Detail Information

Publications11

  1. doi request reprint Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls
    Robin K Kelley
    Helen Diller Family Comprehensive Cancer Center and The Liver Center, University of California San Francisco UCSF, 550 16th St, Box 3211, San Francisco, CA, 94143, USA
    BMC Cancer 15:206. 2015
    ....
  2. pmc Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates
    R K Kelley
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco UCSF, San Francisco, CA 94143, USA
    Ann Oncol 24:1900-7. 2013
    ....
  3. ncbi request reprint Predictive biomarkers in advance of a companion drug: ahead of their time?
    Robin K Kelley
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94143, USA
    J Natl Compr Canc Netw 10:303-9. 2012
    ..A great need exists for comprehensive and dynamic practice guidelines for all types of biomarker testing according to tumor type...
  4. pmc Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
    Robin K Kelley
    University of California, San Francisco, The Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 10:73-80. 2011
    ..Current evidence for both of these assays is described below, concluding with a discussion of potential future directions for gene expression profiling in colon cancer risk stratification and treatment decision making...
  5. pmc Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer
    Robin K Kelley
    Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
    J Natl Compr Canc Netw 9:13-25. 2011
    ..Potential implications of this conclusion and future directions for research are discussed...
  6. ncbi request reprint Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    Am J Clin Oncol 35:411-7. 2012
    ....
  7. doi request reprint A review of hepatocellular carcinoma (HCC) staging systems
    Somasundaram Subramaniam
    Stanford Cancer Institute, Stanford, California, USA
    Chin Clin Oncol 2:33. 2013
    ..Finally, we look ahead to novel systems utilizing molecular markers. It is hoped this review will provide context regarding the use of current staging and scoring methods and a glimpse of what we can expect with future systems. ..
  8. ncbi request reprint A Case Series of Patients with HER2-Overexpressed Primary Metastatic Gastroesophageal Adenocarcinoma
    Pelin Cinar
    Division of Hematology Oncology, Department of Medicine, University of California, San Francisco, CA, U S A
    Anticancer Res 34:7357-60. 2014
    ..Overexpression of the human epidermal growth factor 2 (HER2) is associated with an aggressive metastatic phenotype in patients with breast cancer but its prognostic impact is not well-characterized in gastroesophageal adenocarcinoma...
  9. doi request reprint Multidisciplinary management of hepatocellular carcinoma
    Jennifer Guy
    Department of Medicine, University of California San Francisco, San Francisco, California, USA
    Clin Gastroenterol Hepatol 10:354-62. 2012
    ..We present each specialist's viewpoint on controversies and advances in the management of hepatocellular carcinoma...
  10. doi request reprint Novel therapeutics in hepatocellular carcinoma
    Robin K Kelley
    From the University of California, San Francisco, San Francisco, CA
    Am Soc Clin Oncol Educ Book 2013:137-42. 2013
    ..Collectively, these and other new strategies are needed to make progress in identifying active novel therapeutics for patients with HCC...
  11. pmc Biomarker use in colorectal cancer therapy
    Robin K Kelley
    University of California, San Francisco, CA, USA
    J Natl Compr Canc Netw 9:1293-302. 2011
    ..A selection of biomarkers undergoing validation for future clinical application is presented, and the dynamic and challenging interface between biomarkers in research and clinical practice is discussed...